Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Bessemer Group Inc.

Bessemer Group Inc. lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 625,614 shares of the medical research company's stock after selling 8,425 shares during the period. Bessemer Group Inc. owned about 0.17% of Thermo Fisher Scientific worth $311,305,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Spire Wealth Management raised its holdings in Thermo Fisher Scientific by 24.5% in the first quarter. Spire Wealth Management now owns 1,929 shares of the medical research company's stock worth $960,000 after purchasing an additional 379 shares in the last quarter. Valicenti Advisory Services Inc. increased its stake in shares of Thermo Fisher Scientific by 3.4% in the 1st quarter. Valicenti Advisory Services Inc. now owns 10,118 shares of the medical research company's stock worth $5,035,000 after acquiring an additional 332 shares in the last quarter. Riverbend Wealth Management LLC boosted its stake in Thermo Fisher Scientific by 11.4% during the first quarter. Riverbend Wealth Management LLC now owns 667 shares of the medical research company's stock worth $332,000 after acquiring an additional 68 shares in the last quarter. Global Assets Advisory LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $251,000. Finally, Mill Capital Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 0.3% during the first quarter. Mill Capital Management LLC now owns 79,029 shares of the medical research company's stock valued at $39,325,000 after purchasing an additional 251 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Up 0.3%

Shares of TMO traded up $1.37 during trading hours on Thursday, reaching $412.02. 2,926,073 shares of the company traded hands, compared to its average volume of 1,958,976. The stock's fifty day moving average price is $410.39 and its 200 day moving average price is $485.33. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The firm has a market cap of $155.53 billion, a price-to-earnings ratio of 18.75, a PEG ratio of 2.17 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same period in the previous year, the company posted $5.11 EPS. The business's revenue for the quarter was up .2% compared to the same quarter last year. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Argus lowered their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Barclays lowered their price objective on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating on the stock in a research report on Tuesday. Scotiabank reduced their target price on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a report on Friday, April 25th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Finally, Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $604.05.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.